Luis Ruiz-Avila – Chief Executive Officer (CEO)
He holds a Ph.D. in molecular biology. After ten years of academic research in Spain (CSIC, UB) and USA (Roche, Mount Sinai NY) Luis started his business career in Almirall in 1997 as project manager and business developer. In 2001 leaves Almirall to participate in creating Advancell, one of the first Spanish biotechnology spin-offs, where he served as CEO from its conception until December 2008, when he left his position to create Janus Developments. He was a member of the board of Asebio between 2004 and 2008. He is the founder of CataloniaBio (the Catalan association of biotech companies) and member of its board. He regularly participates in working groups of local institutions, particularly Biocat. From 1st May 2010 he is the interim CEO of Archivel Farma, S.L.

Pere-Joan Cardona – Chief Scientific Officer (CSO)
Mr. Cardona is an MD from the Universitat Autònoma of Barcelona. He is the co-inventor of RUTI®.
Over the course of his professional career he has worked at the Germans Trias i Pujol Hospital both as a researcher and associate lecturer. He is currently Head of the Experimental Tuberculosis Unit.
His recent research has focused on developing the “dynamic hypothesis” which proposes a shift in the way in which the latency of TB infection is understood and thereby offers a new approach when designing new drugs and treatment programmes. He was also one of the Principal Investigators of the Phase I clinical trial performed with RUTI®. Mr. Cardona has written over 30 publications and holds 3 international patents.

Isabel Amat – Chief Pharmaceutical Development Officer (CPDO)
Ms. Amat i Riera is a graduate of Chemistry from the University of Barcelona and is the co-inventor of RUTI®, and also one of the founders of the company in 2005.
Ms. Amat i Riera trained at the Sant Pau Hospital Research Institute in Barcelona where she completed her doctoral thesis. She was Head of R&D at Transtechnics Barcelona (liposome research and enhancement) before joining the microbiology group at the Germans Trias i Pujol Hospital to develop RUTI®. From 2003 to 2005 she was responsible for developing the vaccine and was Head of R&D at Archivel Technologies. Since 2005, as Head of Pharmaceutical Development, Ms. Amat i Riera and her team have achieved major targets including registering Archivel Farma as a pharmaceutical laboratory manufacturing sterile products with the AEMPS (Spanish Agency for Drugs and Sanitary Products), and coordinating the production of the clinical batches for the Phase I clinical trial.

Olga Rue - Chief Financial and Administrative Officer (CFO)
Ms. Rue is a graduate of Law from the University of Barcelona and holds a Master of Tax Law, in addition to having taken other specialization courses and seminars. Since the outset of the project she has been involved as an external consultant for Archivel Technologies. Her professional career encompasses the tax, commercial and corporate law fields and she has worked for several law firms. Ms. Rue has been involved in the project since the beginning. She is a member of the Spanish Association of Tax Advisors.